[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"ab44ad05-9bd9-4db7-9ebb-ab1b8496e06f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190027","created_at":"2025-09-27T08:39:53.097Z","updated_at":"2025-09-27T08:39:53.097Z","phase":"Phase 1/2","brief_title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","source_id_and_acronym":"NCT07190027","lead_sponsor":"First Affiliated Hospital of Wenzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-09-24"},{"id":"744cefa6-7afb-4f15-a0be-a9b48479230c","acronym":"SURGAN-ICI","url":"https://clinicaltrials.gov/study/NCT07177105","created_at":"2025-09-20T07:06:49.764Z","updated_at":"2025-09-20T07:06:49.764Z","phase":"Phase 2","brief_title":"Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC","source_id_and_acronym":"NCT07177105 - SURGAN-ICI","lead_sponsor":"Jianxing He","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2025-09-16"},{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"722a2a86-9fad-4d71-874a-87f0351a5eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06925243","created_at":"2025-06-28T16:10:56.066Z","updated_at":"2025-06-28T16:10:56.066Z","phase":"Phase 3","brief_title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06925243","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 682","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-22"},{"id":"9e066b71-7f4b-4632-8ecf-e6e2e35a7dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05427487","created_at":"2022-06-22T21:54:15.197Z","updated_at":"2025-02-25T14:08:55.980Z","phase":"Phase 1","brief_title":"Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT05427487","lead_sponsor":"ImmVirx Pty Ltd","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IVX037"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/17/2023","start_date":" 02/17/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-17"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"},{"id":"b1c10d0d-1701-4204-9a13-70fa02a920af","acronym":"","url":"https://clinicaltrials.gov/study/NCT06776757","created_at":"2025-02-25T20:24:09.804Z","updated_at":"2025-02-25T20:24:09.804Z","phase":"Phase 1/2","brief_title":"Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT06776757","lead_sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Tyvyt (sintilimab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/25/2023","start_date":" 12/25/2023","primary_txt":" Primary completion: 06/25/2025","primary_completion_date":" 06/25/2025","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2025-01-15"},{"id":"6ae1af87-4593-48e3-aff5-d1191e4709dc","acronym":"TORCH-G","url":"https://clinicaltrials.gov/study/NCT06728657","created_at":"2025-02-26T07:20:14.599Z","updated_at":"2025-02-26T07:20:14.599Z","phase":"Phase 2","brief_title":"Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","source_id_and_acronym":"NCT06728657 - TORCH-G","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-12-11"},{"id":"5640ea05-133d-4835-a328-4241c7d9b37f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06602063","created_at":"2025-02-26T08:14:10.716Z","updated_at":"2025-02-26T08:14:10.716Z","phase":"Phase 1/2","brief_title":"Surgery for Ovarian Cancer After PARPi Therapy in Precision","source_id_and_acronym":"NCT06602063","lead_sponsor":"Shanghai Gynecologic Oncology Group","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-11-28"},{"id":"821f93e8-fb88-4f16-baae-9cc1bb7f7041","acronym":"","url":"https://clinicaltrials.gov/study/NCT06698757","created_at":"2025-02-26T13:35:21.472Z","updated_at":"2025-02-26T13:35:21.472Z","phase":"Phase 2","brief_title":"Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/Microsatellite Instability-high, Locally Advanced Colorectal Cancer","source_id_and_acronym":"NCT06698757","lead_sponsor":"Yugui Lian","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 11/15/2027","primary_completion_date":" 11/15/2027","study_txt":" Completion: 11/15/2031","study_completion_date":" 11/15/2031","last_update_posted":"2024-11-21"},{"id":"f109b88e-560a-4598-bc03-b77d5c07ca6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06590844","created_at":"2025-02-27T08:20:21.357Z","updated_at":"2025-02-27T08:20:21.357Z","phase":"Phase 4","brief_title":"\"cindilizumab + Bevacizumab + Coenzyme I for Injection\" in Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT06590844","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tyvyt (sintilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/19/2023","start_date":" 12/19/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-09-11"},{"id":"1844ac4c-7706-4bda-83c3-f18f6ab3c4e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06577194","created_at":"2025-02-27T08:16:49.348Z","updated_at":"2025-02-27T08:16:49.348Z","phase":"Phase 2","brief_title":"A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Concurrent With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT06577194","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-08-29"},{"id":"75a2f882-37f5-404f-a62e-867c007e7b0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06543836","created_at":"2025-02-27T08:03:16.048Z","updated_at":"2025-02-27T08:03:16.048Z","phase":"Phase 2","brief_title":"ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer","source_id_and_acronym":"NCT06543836","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-08-08"},{"id":"1d9df858-02f3-4502-906c-15d18a9ed9f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06494943","created_at":"2025-02-26T14:28:07.615Z","updated_at":"2025-02-26T14:28:07.615Z","phase":"Phase 1","brief_title":"Induction IBI110 and Sintilimab With Chemotherapy In LA HNSCC","source_id_and_acronym":"NCT06494943","lead_sponsor":"Fudan University","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tyvyt (sintilimab) • negalstobart (IBI110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/26/2024","start_date":" 06/26/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-07-10"},{"id":"144bc660-3c94-4a69-b174-23b147056c11","acronym":"","url":"https://clinicaltrials.gov/study/NCT06342167","created_at":"2024-04-02T18:41:55.615Z","updated_at":"2024-07-02T16:34:27.054Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT06342167","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/14/2024","start_date":" 03/14/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-11"},{"id":"a51e9233-d87e-4f50-965b-570d47d1969d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05017103","created_at":"2021-08-23T12:53:06.121Z","updated_at":"2024-07-02T16:34:37.253Z","phase":"Phase 2","brief_title":"Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study","source_id_and_acronym":"NCT05017103","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-06-07"},{"id":"b00e3ffe-752b-49ff-a89f-7a8b1426b4b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05059951","created_at":"2021-09-28T11:53:04.465Z","updated_at":"2024-07-02T16:34:59.258Z","phase":"","brief_title":"Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer","source_id_and_acronym":"NCT05059951","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF","pipe":"","alterations":" ","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tyvyt (sintilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 15000","initiation":"Initiation: 10/03/2021","start_date":" 10/03/2021","primary_txt":" Primary completion: 09/15/2026","primary_completion_date":" 09/15/2026","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-06-04"},{"id":"eb45600d-a134-491a-b1b8-26b3e543335e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06421298","created_at":"2024-05-25T04:21:54.526Z","updated_at":"2024-07-02T16:35:02.560Z","phase":"Phase 2","brief_title":"A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.","source_id_and_acronym":"NCT06421298","lead_sponsor":"Jinghui Wang","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 05/30/2027","primary_completion_date":" 05/30/2027","study_txt":" Completion: 05/30/2027","study_completion_date":" 05/30/2027","last_update_posted":"2024-05-20"},{"id":"1933bc5f-c2a0-4772-ae42-8c2330e0d507","acronym":"","url":"https://clinicaltrials.gov/study/NCT05026736","created_at":"2021-08-30T21:52:59.657Z","updated_at":"2024-07-02T16:35:04.671Z","phase":"Phase 2","brief_title":"Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study","source_id_and_acronym":"NCT05026736","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-05-09"},{"id":"fde29313-2b66-4046-9a0c-576daa035c8e","acronym":"SiARa-CUP","url":"https://clinicaltrials.gov/study/NCT05024968","created_at":"2021-08-27T12:53:02.508Z","updated_at":"2024-07-02T16:35:04.920Z","phase":"Phase 2","brief_title":"Sintilimab in Cancer of Unknown Primary","source_id_and_acronym":"NCT05024968 - SiARa-CUP","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/26/2021","start_date":" 08/26/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-05-08"},{"id":"549a7364-24ed-4cb0-a1a5-48fe62ef459e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804526","created_at":"2023-04-07T13:03:06.963Z","updated_at":"2024-07-02T16:35:07.029Z","phase":"Phase 1/2","brief_title":"A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours","source_id_and_acronym":"NCT05804526","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-30"},{"id":"4778a574-5f01-405a-9873-c9cc5d26ae19","acronym":"","url":"https://clinicaltrials.gov/study/NCT03903705","created_at":"2021-01-18T19:12:53.641Z","updated_at":"2024-07-02T16:35:07.454Z","phase":"Phase 1/2","brief_title":": A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors","source_id_and_acronym":"NCT03903705","lead_sponsor":"Hutchmed","biomarkers":" PD-L1 • ALK • ROS1 • IFNA1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion","tags":["PD-L1 • ALK • ROS1 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 381","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-25"}]